Skip to main content


Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV

Fig. 1

Aprepitant inhibits HIV replication in MDM. a Monocytes were isolated from the blood samples from 125 depressed and not depressed HIV negative subjects (for detailed description of donor population see “HIV infection and depression: patients utilized for ex vivo analysis”). Following differentiation for 7 days MDM were infected with HIV Bal. Macrophages from each subject were exposed to all four experimental conditions as indicated (1, 5 and 10 μM concentrations of aprepitant). Control, HIV infected MDM were treated with aprepitant vehicle, 0.001 % DMSO. RNA was collected 7 days after infection and assayed for expression of HIV GAG by real time RT PCR using the GAPDH housekeeping gene for normalization. GAG expression in control (non-treated) cultures were designated as 100 %; *p < 0.0001 between all groups including control were obtained through one-way ANOVA with post-test analysis by Bonferroni’s Multiple Comparison Test indicating significant difference between all groups in pair wise comparison. b Aprepitant added to DMEM 10 % FBS media or MDM cultures at a concentration of 1 μM (0.53 μg/ml) on day 0 and measured on days 0, 1, 2, 3 and 7. Results are presented as mean ± SD for three independent experiments

Back to article page